Navigation Links
OncoGenex Announces Publication of Custirsen Phase II Clinical and Pre-Clinical Data in Leading Cancer Journals
Date:9/6/2011

rsen in first-line treatment of advanced, unresectable non-small cell lung cancer. OGX-427 is in Phase II clinical development; CSP-9222 and OGX-225 are currently in pre-clinical development.

OncoGenex' Forward Looking Statements

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning our anticipated product development activities, such as expected clinical trial initiation and completion dates, patient enrollment targets, proposed amendments to our ongoing clinical trial design and the timing and possibility for approval by the FDA thereof, the timing and costs of our product development activities and the potential benefits of our product candidates. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements. Such forward-looking statements are subject to risks and uncertainties, including, among others, the risk of delays in our expected clinical trials and the uncertainties regarding patient enrollment rates, the risk that the FDA does not approve our proposed amendment to the Saturn trial design in a timely fashion or at all, the risk that our product candidates do not obtain the requisite regulatory approvals to commercialize, the risk that new developments in the rapidly evolving prostate cancer therapy landscape require additional changes in our clinical trial design or limit the potential benefits of our product and the other factors described in our risk factors set forth in our filings with the Securities and Exchange Commission from time
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Pharmaceuticals Names Michelle Burris Executive Vice President, Operations and Chief Financial Officer
2. OncoGenex Reports Third Quarter Financial Results
3. OncoGenex Pharmaceuticals, Inc. Closes $50 Million Public Offering
4. OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering
5. OncoGenex Pharmaceuticals, Inc. Announces Proposed Public Offering
6. OncoGenex Pharmaceuticals to Present at the 9th Annual BIO Investor Forum
7. TEVA AND ONCOGENEX ANNOUNCE INITIATION OF SECOND PHASE 3 TRIAL OF CUSTIRSEN IN MEN WITH METASTATIC PROSTATE CANCER
8. OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
9. OncoGenex Reports Second Quarter Financial Results
10. OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
11. OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... August 27, 2015 , ... Capital Edge Consulting , a nationwide ... pleased to announce their ranking as one of the top 5000 companies listed on ... companies across the nation. , “It is truly an honor to be recognized as ...
(Date:8/27/2015)... /PRNewswire/ - Portage Biotech Inc. ("Portage") (OTC Market: ... Holding Company Limited (Biohaven), announced today that dosing ... BHV-0223, a glutamate modulating agent. Biohaven filed an ... obtained clearance from the U.S. Food and Drug ... holds 54% equity interest in Biohaven, a private ...
(Date:8/27/2015)...  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading ... today announced that executives from the company will present ... , Pedro Lichtinger , Chief ... Annual Global Investment Conference on Wednesday, September 10, 2015 ... in New York City . ...
(Date:8/27/2015)... , Aug. 27, 2015 HUYA Bioscience International ... of the Japan Society of HTLV-1, held this week ... The purpose of the Society is to promote research ... development of medical technology and research related to these ... "HUYA is proud to support this prestigious ...
Breaking Biology Technology:Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 2Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4Asterias Biotherapeutics to Present at Upcoming Investor Conferences 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 4
... and NEW DELHI, India, July 17 ... and the stock market, Daiichi Sankyo,Company, Limited ... (NSE/BSE: Ranbaxy/500359) ("Ranbaxy") reiterate that the agreement,between ... the largest,controlling shareholders of Ranbaxy, is binding ...
... ST. LOUIS, July 17 SAFC Supply ... of the Sigma-Aldrich Group (Nasdaq:,SIAL), announced today ... initiative,designed specifically to assist its customers with ... (EU) regulation for chemicals --,Registration, Evaluation, Authorization ...
... of bacteria to produce hydrogen in a bioreactor, with the ... an article in the August issue of Microbiology Today, ... be used to scavenge precious metals from spent automotive catalysts ... , Hydrogen has three times more potential energy by weight ...
Cached Biology Technology:Daiichi Sankyo and Ranbaxy Confirm Deal Is Binding and Final, Allay Market Rumour and Speculation 2SAFC Supply Solutions Launches REACH-Compliant Products and Support 2SAFC Supply Solutions Launches REACH-Compliant Products and Support 3Fuel from food waste: bacteria provide power 2
(Date:8/25/2015)... BELLEVUE, Wash. , Aug. 25, 2015 /PRNewswire/ ... announced today it will unveil its "Guardian S" snake ... the National Tactical Officers Association Conference on August 30 ... S is the first-ever commercially available energetically autonomous snake ... and in-field trials and is protected by more than ...
(Date:8/20/2015)... ., Aug. 20, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market ... has joined The Smart Card Alliance and the EMV ... Alliance and the Smart Card Alliance Latin America (SCALA) ... industry peers and thought leaders promoting adoption of smart ...
(Date:8/12/2015)... Aug. 12, 2015   MedNet Solutions , an ... spectrum of clinical research, is proud to announce that ... comprehensive SaaS-based eClinical technology platform, has led the way ... two quarters of 2015.   Q2 2015 and Q1 ... measured by contract value sold in the company,s 15 ...
Breaking Biology News(10 mins):Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4MedNet Solutions Experiences Explosive Corporate Growth 2
... identified a new species of mysterious beaked whale based on ... in the Indian and Pacific Oceans over the past 50 ... toothed whales distantly related to sperm whales, are found in ... throughout the world,s oceans. "They are rarely seen at ...
... This news release is available in ... in the body, for instance, during development, or when neurons establish ... ,wrong turn, will generally cause disease or developmental disorders. The cells ... which they then repel after a short period of contact. Among ...
... NY) When the foe is a disease-causing microbe, identifying ... to kill or disable it. Research to gain this ... The Price Family Foundation. The gift to Albert Einstein ... of Oklahoma funds a research collaboration to investigate the structural ...
Cached Biology News:Researchers discover rare new species of deep-diving whale 2Sociable receptors: In pairs, in groups or in a crowd 2Sociable receptors: In pairs, in groups or in a crowd 3Price Family Foundation funds research collaboration between Albert Einstein College of Medicine and University of Oklahoma 2Price Family Foundation funds research collaboration between Albert Einstein College of Medicine and University of Oklahoma 3
... are supplied as 10X concentrated solutions. REact Buffer ... of the REact buffers and one 250 microl ... four 1 ml vials of REact 1 Buffer ... four 1 ml vials of REact 3 Buffer ...
... Apoptosis Assay Kit #4 detects apoptosis ... in the permeability of cell membranes. This ... and propidium iodide nucleic acid stains. YO-PRO-1 ... of apoptotic cells and labels them with ...
Porcine TNF-alpha/TNFSF1A ELISpot Development Module...
Request Info...
Biology Products: